Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 7 Uterine Cervical Neoplasms 2 Rectal Neoplasms 2 Endometrial Neoplasms 2 Uveal Melanoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pleural Effusion, Malignant 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 15 Doxorubicin 8 Docetaxel 8 Radiotherapy 7 Trabectedin 6 Nivolumab 5 pazopanib 4 liposomal doxorubicin 3 Sunitinib 3 Dacarbazine 3 pembrolizumab 2 eribulin 2 durvalumab 2 avelumab 2 Specimen Handling 2 Radiation Dose Hypofractionation 2 Letrozole 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 temsirolimus 1 sotigalimab 1 selinexor 1 sargramostim 1 rucaparib 1 ribociclib 1 regorafenib 1 pegfilgrastim 1 olaratumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leiomyosarcoma × cediranib × Clear all

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡